ESTRING (estradiol) by Pfizer is estrogen receptor agonists [moa]. First approved in 1996.
Drug data last refreshed 3h ago · AI intelligence enriched 3h ago
ESTRING is a vaginal insert containing estradiol, an estrogen receptor agonist approved in 1996 for treating atrophic vaginitis and related urogenital symptoms in postmenopausal women. The extended-release formulation delivers localized estrogen directly to vaginal tissue, minimizing systemic exposure while addressing vaginal atrophy and associated symptoms.
Product is approaching loss of exclusivity with moderate Part D spending; brand defense and market protection initiatives will be critical for team growth and resource allocation.
Estrogen Receptor Agonists
Estrogen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Worked on ESTRING at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on ESTRING offers experience in managing a mature, established brand facing LOE, requiring skills in market defense, payer negotiation, and lifecycle management. This role is ideal for professionals seeking expertise in women's health, specialty care positioning, and navigating the transition from brand protection to generic competition.